@Article{ecn.2011.0282,
AUTHOR = {Afsaneh Morteza, Manouchehr Nakhjavani, Akram Ghadiri-Anari, Alireza Esteghamati, Omid Khalilzadeh},
TITLE = {Serum interleukin-1 and interleukin-6 are correlated neither with oxidized low density lipoprotein, nor with low-grade inflammation in patients with type 2 diabetes},
JOURNAL = {European Cytokine Network},
VOLUME = {22},
YEAR = {2011},
NUMBER = {2},
PAGES = {107--112},
URL = {http://www.techscience.com/ECN/v22n2/65824},
ISSN = {1952-4005},
ABSTRACT = {Introduction. In vitro studies have shown that oxidized, low density lipoprotein (ox-LDL) stimulates
macrophages to release interleukin-6 (IL-6) and interleukin-1β (IL-1β). In this study, we aimed to investigate the
correlation between ox-LDL and IL-6 and IL-1β levels in the peripheral circulation of patients with type 2 diabetes,
and normal controls. We measured serum high sensitivity CRP (hs-CRP) levels in order to define basal inflammation
in patients and controls. Methods. A total of 40 patients with type 2 diabetes, and 40, age, sex, and body mass index
(BMI) -matched healthy adults were enrolled in the study. Fasting blood sugar (FBS), lipid profile, creatinine,
ox-LDL, IL-6, IL-1β and hs-CRP levels were measured. Results. Patients with type 2 diabetes had higher serum
FBS, HbA1C, high density lipoprotein cholesterol, LDL, ox-LDL/LDL ratio and hs-CRP levels than controls. The
higher serum ox-LDL/LDL ratio in patients with type 2 diabetes remained significant after multiple adjustments
for age, BMI, FBS and HbA1C, (0.65 [0.59-0.71] vs 0.49 [0.41-0.56]; p<0.001) using general linear models. Serum
IL-1β levels were significantly higher in women than in men with type 2 diabetes; this was not the case in controls.
Postmenopausal women in patient and control groups had higher serum IL-6 levels than premenopausal women.
There was no significant correlation between serum ox-LDL, ox-LDL/LDL ratio, IL-6, IL-1β and hs-CRP levels in
patients with type 2 diabetes. Conclusion. Inflammatory cytokines such as IL-1β and IL-6 lose their discriminatory
power with respect to chronic inflammation in patients with type 2 diabetes.},
DOI = {10.1684/ecn.2011.0282}
}